NCT04950868View on ClinicalTrials.gov

The Safety, Tolerability, and Effectiveness of Quetiapine in Postpartum Depression

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 18, 2022

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2025

Conditions
Postpartum Depression
Interventions
DRUG

Quetiapine

They will initially be given 25 mg of quetiapine per day. The dose may be increased by 25-50 mg per week, to a maximum dose of 150 mg per day by week 6 of the study.

Trial Locations (1)

N6C 5J1

Parkwood Institute, London

All Listed Sponsors
lead

Verinder Sharma

OTHER